NASDAQ:EVFM - Evofem Biosciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.75
  • Forecasted Upside: 154.55 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.69
▼ -0.0125 (-1.79%)

This chart shows the closing price for EVFM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evofem Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVFM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVFM

Analyst Price Target is $1.75
▲ +154.55% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evofem Biosciences in the last 3 months. The average price target is $1.75, with a high forecast of $2.50 and a low forecast of $1.00. The average price target represents a 154.55% upside from the last price of $0.69.

This chart shows the closing price for EVFM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Evofem Biosciences. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/21/2021HC WainwrightReiterated RatingBuy$4.00 ➝ $2.50Medium
10/14/2021Morgan StanleyDowngradeEqual Weight ➝ UnderweightHigh
8/12/2021Morgan StanleyLower Price TargetEqual Weight$3.00 ➝ $1.00High
6/7/2021HC WainwrightLower Price TargetBuy$7.00 ➝ $4.00High
3/8/2021HC WainwrightLower Price TargetBuy$8.00 ➝ $7.00Medium
10/1/2020Stifel NicolausInitiated CoverageBuy$5.00High
8/20/2020Morgan StanleyInitiated CoverageEqual Weight$3.00High
8/10/2020OppenheimerBoost Price TargetOutperform$18.00 ➝ $25.00Medium
6/9/2020HC WainwrightLower Price TargetBuy$11.00 ➝ $9.00Medium
6/8/2020Piper SandlerInitiated CoverageOverweight$11.00High
5/31/2020Royal Bank of CanadaReiterated RatingBuyLow
5/27/2020OppenheimerBoost Price TargetOutperform$23.00 ➝ $25.00Medium
5/27/2020HC WainwrightReiterated RatingBuy$11.00High
5/25/2020OppenheimerInitiated CoverageBuy$23.00High
5/22/2020Cantor FitzgeraldReiterated RatingBuy$9.00N/A
5/7/2020OppenheimerReiterated RatingBuyHigh
3/25/2020Royal Bank of CanadaReiterated RatingBuy$6.00Low
12/18/2019HC WainwrightReiterated RatingBuy$11.00High
12/11/2019HC WainwrightReiterated RatingBuy$9.00 ➝ $11.00Low
11/27/2019HC WainwrightReiterated RatingBuy$9.00Low
10/17/2019HC WainwrightReiterated RatingBuy$9.00Low
10/16/2019Cantor FitzgeraldReiterated RatingOverweight$9.00Low
5/28/2019HC WainwrightSet Price TargetBuy$9.00High
4/15/2019HC WainwrightReiterated RatingBuyLow
4/12/2019Cantor FitzgeraldSet Price TargetBuy$9.00Low
4/12/2019OppenheimerBoost Price TargetOutperform$9.00 ➝ $11.00Low
3/4/2019Cantor FitzgeraldReiterated RatingBuy$9.00High
2/26/2019Cantor FitzgeraldSet Price TargetBuy$9.00High
1/7/2019HC WainwrightReiterated RatingBuy$12.50Low
12/17/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
12/17/2018OppenheimerSet Price TargetBuy$9.00High
12/10/2018HC WainwrightSet Price TargetBuy$11.00High
11/23/2018Cantor FitzgeraldReiterated RatingOverweightLow
11/16/2018OppenheimerSet Price TargetBuy$9.00High
11/15/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
11/7/2018OppenheimerSet Price TargetBuy$9.00N/A
11/7/2018Cantor FitzgeraldSet Price TargetBuy$9.00Low
10/30/2018Cantor FitzgeraldSet Price TargetBuy$9.00Low
10/4/2018Cantor FitzgeraldSet Price TargetBuy$9.00Medium
9/26/2018Cantor FitzgeraldInitiated CoverageOverweight$9.00High
8/29/2018HC WainwrightReiterated RatingBuy$11.00High
8/6/2018HC WainwrightSet Price TargetBuy$11.00Low
8/3/2018OppenheimerSet Price TargetBuy$9.00High
6/27/2018Royal Bank of CanadaInitiated CoverageOutperform$8.00Low
6/20/2018Roth CapitalInitiated CoverageBuy$15.00High
6/18/2018OppenheimerInitiated CoverageOutperform$9.00High
5/29/2018HC WainwrightSet Price TargetBuy$11.00Medium
3/19/2018HC WainwrightInitiated CoverageBuy ➝ Buy$15.00Medium
(Data available from 10/27/2016 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/27/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Evofem Biosciences logo
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate) a hormone-free vaginal gel and EVO100 an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.69
Low: $0.68
High: $0.70

50 Day Range

MA: $0.77
Low: $0.67
High: $0.89

52 Week Range

Now: $0.69
Low: $0.65
High: $5.53

Volume

2,186,640 shs

Average Volume

6,588,135 shs

Market Capitalization

$106.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evofem Biosciences?

The following equities research analysts have issued reports on Evofem Biosciences in the last twelve months: HC Wainwright, and Morgan Stanley.
View the latest analyst ratings for EVFM.

What is the current price target for Evofem Biosciences?

2 Wall Street analysts have set twelve-month price targets for Evofem Biosciences in the last year. Their average twelve-month price target is $1.75, suggesting a possible upside of 150.0%. HC Wainwright has the highest price target set, predicting EVFM will reach $2.50 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $1.00 for Evofem Biosciences in the next year.
View the latest price targets for EVFM.

What is the current consensus analyst rating for Evofem Biosciences?

Evofem Biosciences currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EVFM, but not buy more shares or sell existing shares.
View the latest ratings for EVFM.

How do I contact Evofem Biosciences' investor relations team?

Evofem Biosciences' physical mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is (858) 550-1900 and its investor relations email address is [email protected] The official website for Evofem Biosciences is www.evofem.com.